Neurogene stops Batten gene therapy after FDA denies request, dealing double dose of bad news Read more 

Incyte's $750M buyout rocked by pause on key trial, asset cull Read more 

Nearing potential FDA approval, BridgeBio shows additional positive data on ATTR-CM candidate acoramidis Read more 

Bionow Neuroscience Conference

The Bionow Neuroscience Conference will gather key academics, clinicians, and industry professionals for an insightful exploration of the challenges and opportunities within the neuroscience sector. [...]

Go to Top